vaccinia
viru
vv
provid
excel
prophylact
immun
variola
viru
caus
agent
smallpox
led
erad
fatal
diseas
world
recent
year
vv
also
success
use
live
vaccin
vector
prevent
erad
infecti
diseas
advantag
deliv
express
foreign
antigen
eukaryot
cell
consider
number
differ
strain
vv
adapt
serv
vaccin
vector
nyvac
nycboh
mva
tian
tan
vv
strain
engin
express
antigen
herp
simplex
viru
hepat
b
viru
rabi
viru
influenza
viru
human
immunodefici
viru
hiv
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndrom
coronaviru
sarscov
pathogen
respect
among
modifi
vaccinia
ankara
mva
probabl
wide
studi
vaccinia
vector
especi
due
excel
safeti
profil
human
mva
vaccin
elicit
level
cytotox
lymphocyt
ctl
respons
compar
induc
replicationcompet
vv
strain
importantli
vaccin
mva
protect
macaqu
pathogen
monkeypox
challeng
mvabas
recombin
vaccin
abl
induc
protect
immun
respons
differ
virus
includ
sarscov
influenza
viru
rsv
immunogen
mva
express
hiv
antigen
howev
satisfactori
describ
recent
human
clinic
trial
moreov
sinc
mva
requir
larg
clinic
dose
pfu
higher
propag
need
special
pathogen
free
spf
primari
chicken
embryo
fibroblast
cef
cell
manufactur
burden
produc
suffici
quantiti
clinic
grade
product
especi
develop
countri
therefor
necessari
studi
vacciniabas
vaccin
vector
studi
carri
investig
whether
differ
vaccinia
vector
would
offer
advantag
especi
induc
protect
immun
respons
critic
issu
differ
vv
vector
may
harbor
distinct
profil
term
immun
modul
host
virul
furthermor
studi
mucos
vaccin
also
critic
major
mode
transmiss
mani
virus
includ
hiv
sarscov
influenza
viru
etc
mucos
surfac
convent
replicationcompet
vaccinia
vector
consid
effect
mucos
vaccin
safeti
issu
may
limit
widespread
use
human
therefor
suggest
attenu
replicationcompet
vaccinia
vector
studi
mucos
vaccin
till
remain
unknown
whether
newli
develop
replicationcompet
modifi
vaccinia
tian
tan
mvtt
would
offer
advantag
nonrepl
mva
mucos
vaccin
test
antigen
construct
ident
promot
genom
locat
two
live
vector
respect
vaccinia
tian
tan
vtt
histor
use
vaccin
million
chines
peopl
worldwid
smallpox
prevent
campaign
led
variola
erad
china
similar
vaccinia
strain
vtt
member
orthopoxviru
genu
although
histor
report
safeti
profil
vtt
human
suggest
vtt
like
exhibit
good
immunogen
moder
reactogen
rel
mild
complic
recent
studi
suggest
intranas
deliveri
vttbase
vaccin
use
combin
dna
induc
strong
hivspecif
immun
respons
safeti
profil
particular
vaccin
mucos
use
mention
public
howev
demonstr
unmodifi
vtt
retain
virul
pathogenc
anim
studi
especi
intranas
administr
data
indic
vtt
modifi
intranas
vaccin
vector
sinc
gener
modifi
vaccinia
tian
tan
mvtt
strain
attenu
virul
vtt
viral
genom
engin
clonal
select
sinc
merck
ctlorient
hiv
vaccin
recent
fail
clinic
trial
becom
desir
identifi
effect
live
vector
elicit
neutral
antibodi
nab
studi
potenti
mvtt
vaccin
vector
induc
nab
specif
report
find
headtohead
comparison
studi
mva
mvtt
vector
mucos
vaccin
major
uniqu
mvtt
attenu
yet
replicationcompet
strain
test
mammalian
cell
spike
glycoprotein
sarscov
use
test
antigen
gene
construct
ident
genom
locat
two
live
vector
gener
vaccin
candid
mvtt
mva
evalu
specif
neutral
antibodi
nab
respons
sarscov
determin
immunogen
profil
two
distinct
live
vaccinia
vector
system
vivo
background
parent
vaccinia
tian
tan
describ
previou
public
modifi
dualpromot
insert
vector
pzcxz
construct
target
genom
region
vtt
correspond
del
iii
region
mva
pzcxz
contain
two
promot
name
psyn
ph
vaccinia
virusspecif
earlylat
promot
use
pzcxz
gene
report
green
fluoresc
protein
gfp
gene
incorpor
genom
vtt
construct
recombin
vaccinia
viru
mvtt
use
homolog
recombin
method
african
green
monkey
kidney
vero
cell
fig
viru
purifi
consecut
plaqu
select
use
gfp
surrog
marker
fluoresc
microscop
stabil
mvtt
determin
doublestain
protein
vaccinia
specif
antigen
foci
ninth
passag
viral
stock
similar
techniqu
recent
publish
use
similar
techniqu
mva
construct
insert
gene
del
iii
region
mva
genom
previous
describ
immunohistochemistri
assay
develop
detect
sarscov
glycoprotein
express
cell
surfac
briefli
vero
cell
grown
cultur
dish
reach
confluenc
subsequ
infect
mvtt
multipl
infect
moi
viral
absorpt
min
cell
wash
three
time
cultur
medium
incub
anoth
hour
h
h
immunostain
incub
cell
fix
cold
solut
methanolaceton
five
min
incub
h
room
temperatur
rabbit
anti
serum
dilut
phosphat
buffer
salin
pb
contain
fetal
bovin
serum
fb
cell
wash
incub
h
room
temperatur
dilut
proteina
conjug
horseradish
peroxidas
zhongshan
biotech
beij
china
wash
color
develop
incub
min
substrat
solut
consist
ml
ethanol
satur
dianishidin
sigma
st
loui
mo
usa
solut
ml
pb
western
blot
analysi
cell
infect
vaccinia
viru
multipl
infect
moi
h
transfect
cell
lyse
ice
minut
lysi
buffer
mm
trishcl
ph
mm
nacl
mm
ethylenediaminetetraacet
acid
edta
glycerol
pepstatin
leupeptin
pefabloc
clear
lysat
rpm
minut
boil
minut
run
sodium
dodecyl
gel
electrophoresi
invitrogen
carlsbad
ca
usa
protein
transfer
polyvinyliden
difluorid
membran
invitrogen
blot
block
milk
bsa
pb
wash
incub
rabbit
anti
ratio
polyclon
antibodi
blot
wash
incub
dilut
prote
horseradish
peroxidas
hrp
conjug
biorad
hercul
ca
usa
immunofluoresc
measur
enhanc
chemoluminesc
ecl
plu
kit
amersham
bioscienc
piscataway
nj
usa
vtt
mvtt
viral
stock
propag
vero
cell
purifi
centrifug
sucros
cushion
mva
stock
prepar
purifi
use
chicken
embryo
fibroblast
cef
cell
accord
procedur
describ
previous
viral
stock
titrat
simultan
cef
plaqu
form
assay
use
crystal
violet
stain
count
plaqu
gfp
express
determin
viral
virul
vivo
two
group
sixweek
old
mice
inocul
pfu
mvtt
via
rout
respect
group
six
mice
viral
virul
subsequ
determin
daili
measur
anim
bodi
weight
chang
period
day
dose
escal
studi
group
three
sixweekold
femal
balbc
mice
immun
intramuscular
im
inject
mvtt
mva
week
group
mice
inocul
one
pfu
either
virus
salin
control
determin
best
rout
vaccin
suboptim
dose
pfu
use
group
three
balbc
mice
week
vaccin
rout
includ
intranas
intraor
io
intrarect
ir
intraderm
id
subcutan
sc
intraperiton
ip
inocul
mucos
vaccin
studi
group
balbc
mice
immun
pfu
viru
week
via
im
io
ir
rout
vaccin
mice
sacrif
two
week
second
inject
blood
sampl
use
analysi
anim
experiment
protocol
approv
institut
anim
ethic
committe
follow
nation
guidelin
use
anim
scientif
research
experi
evalu
whether
preexposur
vtt
would
interfer
immunogen
mvtt
group
sixweekold
balbc
mice
immun
sc
inject
pfu
vtt
day
mice
kept
six
month
inocul
pfu
mvtt
mva
twice
one
month
interv
via
im
sc
io
rout
respect
sera
collect
two
week
inocul
analysi
parallel
placebo
control
group
sixweekold
balbc
mice
immun
sc
inject
pb
day
mice
kept
six
month
inocul
pfu
mvtt
pfu
mva
pb
twice
one
month
interv
via
im
sc
io
rout
respect
sera
collect
two
week
inocul
analysi
pseudovirusbas
neutral
assay
establish
determin
humor
immun
respons
sarscov
pseudotyp
viru
gener
cotransfect
cell
two
plasmid
carri
optim
gene
human
immunodefici
viru
type
backbon
respect
previous
describ
neutral
activ
heatinactiv
sera
min
determin
mix
ng
pseudotyp
viru
dilut
serum
h
neutral
mixtur
combin
ng
polybren
medium
ad
cell
cell
per
well
cell
wash
pb
lyse
cell
cultur
lysi
reagent
promega
madison
wi
usa
h
infect
luciferas
activ
measur
percentag
neutral
calcul
assay
vaccinia
neutral
base
previou
public
use
fluorescenceactiv
cell
sort
fac
analysi
assay
vttbase
recombin
viru
construct
express
green
fluoresc
protein
gfp
gene
previous
gener
mvabas
vaccin
mva
abl
prevent
sarscov
infect
chines
rhesu
monkey
order
make
reason
comparison
mva
mvtt
live
vaccin
vector
use
strategi
construct
mva
gener
mvttbase
vaccin
modifi
shuttl
vector
pzcxz
construct
target
gene
mvtt
genom
locat
correspond
del
iii
region
mva
fig
shuttl
vector
contain
dual
promot
allow
simultan
express
two
target
gene
within
vector
gene
sarscov
construct
strong
synthet
promot
psyn
wherea
report
gfp
gene
separ
rel
weaker
promot
ph
fig
sinc
gene
includ
within
insert
frame
gfp
serv
surrog
marker
select
recombin
vtt
carri
gene
use
techniqu
abl
gener
purifi
recombin
viru
mvtt
posit
plaqu
select
fluoresc
microscop
subsequ
confirm
immunohistochem
assay
use
glycoprotein
specif
antibodi
fig
left
imag
moreov
protein
also
detect
rabbit
antibodi
bound
ntermin
amino
acid
protein
western
blot
analysi
protein
appear
posit
kda
consist
previou
observ
fig
compar
level
sglycoprotein
express
detect
cef
cell
use
ident
dose
viral
inocul
fig
addit
mvtt
passag
vero
cell
nine
time
evalu
foci
passag
found
foci
express
glycoprotein
vaccinia
protein
passag
therefor
lead
loss
glycoprotein
express
indic
mvtt
like
genet
stabl
consid
insert
foreign
gene
product
might
alter
virul
mvtt
evalu
vivo
toxic
mvtt
anim
inbr
balbc
mous
chosen
assess
mvtt
virul
previous
describ
data
collect
pfu
group
present
figur
two
independ
experi
conduct
consist
result
obtain
none
mice
die
experi
period
furthermor
mice
infect
mvtt
show
sign
weight
loss
fig
bodi
weight
chang
mice
infect
mvtt
compar
control
mice
result
suggest
mvtt
like
retain
attenu
phenotyp
like
safe
intranas
vaccin
describ
previous
pseudotypebas
neutral
assay
establish
character
immun
sera
gener
mice
major
advantag
assay
elimin
use
live
sarscov
tradit
neutral
assay
use
assay
measur
serum
neutral
activ
anim
immun
mva
mvtt
total
six
group
mice
immun
either
mva
mvtt
respect
im
inocul
three
mice
one
group
given
pfu
vaccin
anim
immun
twice
threeweek
interv
serum
sampl
collect
subject
neutral
assay
two
week
second
immun
control
three
addit
mice
receiv
placebo
depict
fig
sinc
differ
two
threefold
base
valu
inhibitori
concentr
like
mva
induc
slightli
higher
level
nab
mvtt
via
im
inocul
experiment
condit
two
independ
immun
experi
conduct
similar
result
obtain
moreov
clear
dose
depend
among
three
mva
mvtt
dose
group
valu
reach
highdos
group
contrast
group
control
mice
yield
nab
explor
potenti
use
mva
mvtt
mucos
vaccin
vector
test
two
vaccin
mice
seven
group
three
balbc
mice
immun
via
io
im
ir
id
ip
sc
rout
use
ident
suboptim
dose
pfu
respect
chose
suboptim
dose
order
avoid
plateau
effort
immun
respons
high
dose
inocul
mice
similar
im
inocul
anim
immun
twice
threeweek
interv
serum
sampl
collect
pool
equal
volum
subsequ
subject
neutral
assay
two
week
second
immun
control
three
mice
receiv
placebo
shown
fig
signific
level
nab
induc
mice
immun
mva
except
im
sc
rout
less
fifti
percent
viru
neutral
sera
dilut
rest
group
particular
io
immun
induc
antibodi
capabl
neutral
viru
dilut
contrast
mvtt
induc
much
higher
level
sarscovspecif
nab
mice
immun
mvtt
via
io
rout
inocul
fig
fifti
percent
viru
neutral
sera
dilut
least
better
mva
fig
level
respons
base
approxim
higher
base
im
vaccin
dose
inoculum
use
fig
therefor
mvtt
superior
mva
deliv
via
io
rout
experi
placebo
group
control
mice
yield
detect
nab
consid
preexist
immun
would
interfer
effect
live
viral
vectorbas
vaccin
sought
determin
whether
would
case
mvtt
mva
vaccin
address
issu
properli
four
group
four
mice
inocul
pfu
vtt
via
io
rout
respect
anoth
four
group
mice
receiv
placebo
six
month
rest
anim
vaccin
twice
pfu
mvtt
mva
month
interv
via
autolog
rout
subsequ
subject
neutral
assay
two
week
second
immun
found
premucos
exposur
wildtyp
vtt
profound
effect
effect
mvtt
mva
vaccin
neutral
antibodi
respons
detect
among
mice
previous
expos
wildtyp
vtt
serum
dilut
note
pfu
highest
dose
possibl
mucos
vaccin
base
concentr
viral
stock
base
placebo
mice
inocul
mvtt
develop
io
higher
level
nab
respons
receiv
mva
fig
appar
mva
pfu
fig
requir
induc
similar
level
nab
elicit
mvtt
pfu
fig
via
either
io
inocul
due
suppress
mvtt
previou
experi
shown
fig
sought
investig
situat
mimic
human
smallpox
vaccin
case
six
experiment
group
four
mice
preinocul
pfu
vtt
via
sc
rout
anoth
three
group
mice
receiv
placebo
six
month
rest
one
experiment
control
group
anim
vaccin
twice
pfu
mva
mvtt
month
interv
via
io
im
rout
respect
serum
sampl
subsequ
subject
neutral
assay
two
week
second
immun
interestingli
sc
preexposur
vtt
much
less
interfer
immunogen
mvtt
deliv
use
heterolog
rout
sc
preexposur
vtt
io
fig
fig
still
abl
induc
higher
level
anti
nab
respons
compar
im
immun
second
mucos
vaccin
fig
reduc
respons
howev
observ
io
fig
fig
compar
anim
without
preexposur
vtt
contrast
sc
preexposur
vtt
profound
neg
effect
subsequ
mva
mucos
vaccin
two
vaccin
induc
nab
fig
consid
mvtt
induc
variabl
level
anti
nab
differ
rout
inocul
use
fig
sought
determin
whether
similar
effect
appli
antivtt
vector
immun
respons
address
issu
measur
level
antivtt
nab
mice
three
week
six
month
vtt
vaccin
use
facsbas
neutral
assay
base
valu
obviou
higher
level
antivtt
nab
induc
via
io
via
sc
inocul
administr
mva
mvtt
tabl
find
suggest
higher
level
antivtt
nab
probabl
affect
effect
subsequ
mva
mvtt
vaccin
fig
interestingli
averag
titer
among
subcutan
vaccin
mice
much
less
effect
subsequ
io
mvtt
vaccin
fig
compar
im
rout
fig
similar
find
obtain
mva
fig
addit
determin
anti
nab
respons
presenc
preexist
antivtt
nab
three
week
first
immun
mva
mvtt
found
io
inocul
mvtt
abl
induc
anti
nab
respons
fig
respons
enhanc
second
inocul
mvtt
via
io
fig
fig
rout
second
immun
also
significantli
boost
anti
nab
respons
mvtt
via
im
fig
mva
via
fig
inocul
respect
therefor
second
mvtt
immun
necessari
boost
nab
respons
presenc
preexist
antivtt
immun
mvtt
offer
greater
advantag
mva
induc
high
level
system
nab
respons
sarscov
mucos
rout
vaccin
consid
induct
nab
one
key
element
success
vaccin
chose
use
spike
glycoprotein
sar
coronaviru
test
antigen
understand
immunogen
profil
mva
mvtt
anoth
reason
choos
glycoprotein
previous
demonstr
mva
induc
protect
nab
contribut
protect
pathogen
sarscov
infect
chines
macaqu
make
fair
comparison
gene
sarscov
construct
equival
genom
locat
two
live
vector
fig
found
mva
induc
higher
level
nab
respons
mvtt
mice
via
im
rout
inocul
use
suboptim
dose
fig
find
suggest
possibl
replic
mvtt
seem
offer
much
advantag
deliv
intramuscularli
system
way
vaccin
notic
advantag
mva
im
immun
reduc
higher
dose
vaccin
test
fig
observ
suggest
mva
probabl
reach
plateau
nab
respons
given
nonrepl
natur
anoth
possibl
relat
experiment
set
long
rest
period
six
month
anim
receiv
placebo
inocul
fig
howev
found
io
inocul
mvtt
induc
highest
level
nab
respons
least
higher
mva
use
suboptim
dose
pfu
fig
moreov
demonstr
minimum
mva
pfu
fig
requir
order
induc
similar
level
nab
elicit
pfu
mvtt
fig
via
either
io
inocul
find
new
suggest
much
higher
minim
dose
requir
mva
immunogen
via
mucos
vaccin
similar
result
report
compar
replic
vaccinia
strain
mva
induc
nab
respons
sinc
level
nab
respons
higher
induc
via
im
rout
find
suggest
mvtt
superior
mva
deliv
via
io
rout
possibl
explain
find
first
mvtt
may
target
mucosaassoci
antigen
present
cell
effici
second
replic
compet
mvtt
may
growth
advantag
mucos
tissu
provid
continu
immun
stimul
third
mvtt
may
contain
mucosaspecif
immun
regulatori
protein
mva
studi
need
determin
underlin
mechan
mvttsmediat
mucos
vaccin
data
provid
direct
evid
use
differ
vaccinia
vector
may
produc
significantli
differ
immunogen
profil
ident
test
antigen
mvtt
system
may
potenti
assist
weak
viral
immunogen
eg
induc
better
nab
respons
end
intranas
deliveri
vttbase
vaccin
use
combin
dna
induc
strong
specif
immun
respons
recent
small
anim
studi
sinc
vtt
strain
may
come
differ
sourc
display
distinct
vivo
toxic
immunogen
profil
vector
aim
clinic
use
care
studi
mucos
vaccin
overcom
preexist
immun
induc
sc
rout
vaccin
wildtyp
vtt
preexist
immun
often
issu
relat
effect
live
viral
vectorbas
vaccin
also
critic
issu
clinic
develop
vacciniabas
vaccin
consist
previou
find
vacciniabas
vector
found
premucos
exposur
wildtyp
vtt
profound
effect
prevent
subsequ
nab
respons
use
rout
vaccin
mvtt
fig
contrast
preexposur
wildtyp
vtt
sc
rout
mucos
vaccin
via
either
io
inocul
abl
overcom
preexist
immun
respons
vector
induc
high
level
anti
nab
fig
sinc
latter
situat
mimic
convent
smallpox
vaccin
data
critic
implic
million
peopl
histor
vaccin
vtt
skin
scarif
support
notion
found
vttvaccin
chines
peopl
maintain
low
level
nab
data
shown
mucos
vaccin
noninvas
needless
procedur
great
implic
larg
scale
vaccin
program
develop
countri
especi
nation
huge
popul
addit
replic
compet
natur
mvtt
permit
minim
dose
vaccin
reduc
manufactur
burden
make
mvttbase
vaccin
becom
cost
effect
mvtt
therefor
attract
attenu
replicatingcompet
vaccinia
vector
mucos
vaccin
approach
howev
assist
mucos
deliveri
mvttbase
vaccin
studi
overcom
antivector
preexist
immun
mucos
vaccin
may
offer
great
advantag
induc
protect
immun
respons
mucos
site
viral
transmiss
consist
anti
nab
respons
induc
mvtt
io
inocul
wtvtt
also
induc
much
higher
level
nab
respons
viral
vector
sc
vaccin
tabl
fact
antivtt
respons
probabl
play
critic
role
elimin
subsequ
inocul
mvtt
autolog
rout
prevent
viral
dissemin
therefor
prevent
induct
nab
respons
glycoprotein
one
hand
data
suggest
vtt
mvtt
probabl
offer
great
advantag
induc
protect
nab
respons
mucos
site
viral
transmiss
hand
data
highlight
import
proper
select
vaccin
rout
vtt
mvttbase
vaccin
vector
said
recommend
use
vtt
vaccin
vector
mucos
vaccin
due
vivo
toxic
pathogen
unexpectedli
abl
detect
anti
neutral
iga
activ
saliva
anim
vaccin
either
mva
mvtt
via
rout
vaccin
one
possibl
mva
mvtt
dominantli
induc
neutral
igg
respons
block
viral
transmiss
dissemin
also
evalu
supernat
homogen
lung
intestin
due
technic
difficulti
exclud
nab
contamin
blood
result
present
care
studi
need
determin
whether
mvtt
system
would
offer
advantag
induc
nab
cell
mediat
immun
respons
mucos
site
viral
antigen
eg
also
test
determin
whether
find
antigendepend
conclus
replicationcompet
vaccinia
vector
mvtt
superior
mva
induc
high
level
neutral
antibodi
via
mucos
vaccin
moreov
mucos
vaccin
may
potenti
offer
signific
advantag
overcom
preexist
antivv
immun
peopl
previous
receiv
smallpox
vaccin
mvtt
therefor
attract
live
viral
vector
develop
futur
mucos
vaccin
